CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
Mené sur des patients atteints d'un cancer de la tête et du cou récidivant ou de stade métastatique, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, du nivolumab en traitement de première ligne (durée minimum de suivi : 11,4 mois)
Nivolumab significantly improved overall survival (OS) vs investigator’s choice (IC) of chemotherapy at the primary analysis of randomized, open‐label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow‐up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first‐line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting. The Oncologist 2018